Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review

References

• SiegelRLMillerKDJemalACancer statisticsCA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• StraubharASoissonAPDodsonMSimonsESuccessful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesteroneGynecol Oncol Rep201721101228560298
   PubMedGoogle Scholar
• SkrzypczakMMerxISchüler-ToprakSMolecular profiling of estrogen receptor α and progesterone receptor transcript variants in endometrial cancerSteroids201510412212826428028
   PubMedGoogle Scholar
• LookKStage I–II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiationInt J Gynecol Cancer200212323724912060444
   PubMedGoogle Scholar
• CreutzbergCLvan PuttenWLKoperPCSurgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trialLancet200035592131404141110791524
   PubMed Web of Science ®Google Scholar
• MaggiRLissoniASpinaFAdjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trialBr J Cancer200695326627116868539
   PubMed Web of Science ®Google Scholar
• DuntonCJPfeiferSMBraitmanLEMorganMACarlsonJAMikutaJJTreatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamideGynecol Oncol19914121131162050302
   PubMedGoogle Scholar
• BestvinaCMFlemingGFChemotherapy for endometrial cancer in adjuvant and advanced disease settingsOncologist201621101250125927412393
   PubMedGoogle Scholar
• BallHGBlessingJALentzSSMutchDGA phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group studyGynecol Oncol19966222782818751561
   PubMedGoogle Scholar
• LincolnSBlessingJALeeRBRoceretoTFActivity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group studyGynecol Oncol200388327728112648575
   PubMed Web of Science ®Google Scholar
• YangLRenBLiHEnhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patientsCancer Immunol Immunother2013621657322744010
   PubMed Web of Science ®Google Scholar
• Schmidt-WolfILefterovaPMehtaBPhenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cellsExp Hematol19932113167316797694868
   PubMed Web of Science ®Google Scholar
• Schmidt-WolfINegrinRSKiemHPBlumeKGWeissmanILUse of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activityJ Exp Med199117411391491711560
   PubMed Web of Science ®Google Scholar
• ChungMJParkJYBangSParkSWSongSYPhase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancerCancer Immunol Immunother201463993994624916038
   PubMed Web of Science ®Google Scholar
• LiuLZhangWQiXRandomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinomaClin Cancer Res20121861751175922275504
   PubMed Web of Science ®Google Scholar
• ZhuXXuYZhouJPanXA clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancerGenet Mol Res20141431022810235
   Google Scholar
• OliosoPGiancolaRDi RitiMContentoAAccorsiPIaconeAImmunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trialHematol Oncol200927313013919294626
   PubMed Web of Science ®Google Scholar
• EisenhauerETherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• MartenARenothSVon Lilienfeld-ToalMEnhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cellsHaematologica200186101029103711602408
   PubMed Web of Science ®Google Scholar
• ZhangZZhaoXZhangTPhenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord bloodCytotherapy2015171869725457278
   PubMed Web of Science ®Google Scholar
• PanKGuanXXLiYQClinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancerClin Cancer Res201420113003301124668644
   PubMedGoogle Scholar
• JiangJXuNWuCTreatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cellsAnticancer Res2006263B2237224216821594
   PubMed Web of Science ®Google Scholar
• PardollDDoes the immune system see tumors as foreign or self?Ann Rev Immunol200321180783912615893
   PubMedGoogle Scholar
• WongkajornsilpAWamanuttajindaVKasetsinsombatKSunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3+ CD56+ subset through the co-culturing dendritic cellsPLoS One20138e7898024232460
   PubMedGoogle Scholar
• ZouWImmunosuppressive networks in the tumour environment and their therapeutic relevanceNature Rev Cancer20055426327415776005
   PubMed Web of Science ®Google Scholar
• YuJZhangWJiangHLiHCaoSRenXCD4+ T cells in CIKs (CD4+ CIKs) reversed resistance to Fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-γ stimulationCancer Biother Radiopharm200823334235418593367
   PubMedGoogle Scholar
• KarimiMCaoTMBakerJAVernerisMRSoaresLNegrinRSSilencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cellsJ Immunol2005175127819782816339517
   PubMed Web of Science ®Google Scholar
• JamiesonAMDiefenbachAMcMahonCWXiongNCarlyleJRRauletDHThe role of the NKG2D immunoreceptor in immune cell activation and natural killingImmunity2002171192912150888
   PubMed Web of Science ®Google Scholar
• HongengSPctviscsSWorapongpaiboonSRcrkamnuaychokeBPakakasamaSJootarSGeneration of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cellsInt J Hematol200377217517912627854
   PubMed Web of Science ®Google Scholar
• NagarajSZiskeCSchmidt-WolfIGHuman cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transferGenet Vaccines Ther2004211215329148
   PubMedGoogle Scholar
• HuiDQiangLJianWTiZDaLuKA randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinomaDig Liver Dis2009411364118818130
   PubMedGoogle Scholar
• WuCJiangJShiLXuNProspective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancerAnticancer Res2008286B3997400219192663
   PubMed Web of Science ®Google Scholar
• JiangJTShenYPWuCPIncreasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patientsWorld J Gastroenterol201016486155616221182234
   PubMed Web of Science ®Google Scholar